IRD (Opus Genetics) Insider Ownership: 11.02 % (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRD Opus Genetics Inc IRD
24 GF Score
Price $3.41
GF Value $0.36
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Opus Genetics Insider Ownership?

Opus Genetics IRD +1.49% 24 Insider Ownership is 11.02 % as of Jul. 29, 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.36 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Opus Genetics's insider ownership is 11.02%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Opus Genetics's Institutional Ownership is 58.66%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Opus Genetics's Float Percentage Of Total Shares Outstanding is 95.06%.

Opus Genetics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Opus Genetics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics Insider Ownership Chart

Opus Genetics Historical Data

The historical data trend for Opus Genetics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 9.38 9.38 10.94 11.27 11.23 9.71 13.06 13.06 11.18 11.02
IRD
24GF Score
Opus Genetics Inc IRD
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Opus Genetics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 11.02 % mean?
Opus Genetics (IRD) has a Insider Ownership of 11.02 % as of Jul. 29, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Opus Genetics and its competitors.
Is Opus Genetics' Insider Ownership too high?
Opus Genetics' current Insider Ownership is 11.02 %. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Insider Ownership compare to TTRX and VRXA?
Opus Genetics' Insider Ownership of 11.02 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Opus Genetics and its competitors. Opus Genetics's current Insider Ownership is 11.02 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.36, compared to a current price of $3.41 — trading 847.2% above its estimated fair value. The current Insider Ownership is 11.02 %. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Opus Genetics (IRD), the current Insider Ownership is 11.02 % as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $3.41 is trading 847.2% above its estimated GF Value™ of $0.36. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • Insider Ownership: 11.02 %
  • GF Value™: $0.36 vs. price of $3.41 (847.2% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score

Get the complete analysis for IRD

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.41
Price
$0.36
GF Value